News

Charité and Sanofi broaden alliance
Enlarge image

BusinessGermanyFrance

Charité and Sanofi broaden alliance

28.09.2012 - German university hospital Charité and French pharma company Sanofi have agreed to expand their joint research efforts to the field of diabetes.

The partnership of the Charité and Sanofi had begun in summer 2010, initially with a focus in the field of stroke research. Following a decision on 27 September, scientists and clinicians from both sides will now work together in the field of diabetes research as well. The goal is to better understand the medical needs of patients and to find new targeted approaches to cure or treat the disease.

The partners have already agreed on a first target molecule to investigate further. Researchers from Charité discovered the yet undisclosed molecule, which will now fuel a core project at the newly founded Sanofi-Charité-diabetic laboratory. The target molecule seems to be promising, as results from laboratory tests indicate that it inhibition might protect the body from diet-and age-induced obesity and insulin resistance. “With Charité we have built a highly efficient scientific cooperation over the past two years,” said Jochen Maas, Director of Research and Development of Sanofi-Aventis Deutschland GmbH and head of the German research and development center of Sanofi.

Karl Max Einhäupl, CEO of the Charité, welcomed the enhanced cooperation as well: “Diabetes is a major challenge for our health system. Bringing together the clinical experience and the academic performance of physicians and scientists of the Charité with the development and application expertise of Sanofi, will generate valuable inputs for the development of successful diabetes therapies.”

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-03/charite-and-sanofi-broaden-alliance.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ANALYTIK JENA14.00 EUR0.07%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

TOP

  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%

TOP

  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR230.7%

FLOP

  • CYTOS1.40 CHF-53.0%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 29.03.2015